Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells.

Naguib A, Mathew G, Reczek CR, Watrud K, Ambrico A, Herzka T, Salas IC, Lee MF, El-Amine N, Zheng W, Di Francesco ME, Marszalek JR, Pappin DJ, Chandel NS, Trotman LC.

Cell Rep. 2018 Apr 3;23(1):58-67. doi: 10.1016/j.celrep.2018.03.032.

2.

Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M, Cox H, Hakker I, Nowak DG, Laze J, Llukani E, Srivastava A, Gruschow S, Yadav SS, Robinson B, Atwal G, Trotman LC, Lepor H, Hicks J, Wigler M, Krasnitz A.

Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.

PMID:
29180472
3.

Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, Tuveson DA, Trotman LC, Kinney JB, Sordella R.

Nat Commun. 2017 Feb 22;8:14370. doi: 10.1038/ncomms14370.

4.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, Nasar A, Castillo-Martin M, Cordon-Cardo C, Wilkinson JE, Powers S, Sordella R, Altorki NK, Mittal V, Stiles BM, Plafker SM, Trotman LC.

J Cell Biol. 2017 Mar 6;216(3):641-656. doi: 10.1083/jcb.201604025. Epub 2017 Feb 13.

5.

PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers.

Labbé DP, Uetani N, Vinette V, Lessard L, Aubry I, Migon E, Sirois J, Haigh JJ, Bégin LR, Trotman LC, Paquet M, Tremblay ML.

Cancer Res. 2016 Jun 1;76(11):3130-5. doi: 10.1158/0008-5472.CAN-15-1501. Epub 2016 Mar 28.

6.

PTEN functions by recruitment to cytoplasmic vesicles.

Naguib A, Bencze G, Cho H, Zheng W, Tocilj A, Elkayam E, Faehnle CR, Jaber N, Pratt CP, Chen M, Zong WX, Marks MS, Joshua-Tor L, Pappin DJ, Trotman LC.

Mol Cell. 2015 Apr 16;58(2):255-68. doi: 10.1016/j.molcel.2015.03.011. Epub 2015 Apr 9.

7.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

8.

Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.

Cho H, Herzka T, Stahlhut C, Watrud K, Robinson BD, Trotman LC.

Methods. 2015 May;77-78:197-204. doi: 10.1016/j.ymeth.2014.12.022. Epub 2015 Jan 12.

9.

p53 mutations change phosphatidylinositol acyl chain composition.

Naguib A, Bencze G, Engle DD, Chio II, Herzka T, Watrud K, Bencze S, Tuveson DA, Pappin DJ, Trotman LC.

Cell Rep. 2015 Jan 6;10(1):8-19. doi: 10.1016/j.celrep.2014.12.010. Epub 2014 Dec 24.

10.

Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.

Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):E3957-65. doi: 10.1073/pnas.1404221111. Epub 2014 Sep 8.

11.

A unified nomenclature and amino acid numbering for human PTEN.

Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR.

Sci Signal. 2014 Jul 1;7(332):pe15. doi: 10.1126/scisignal.2005560.

12.

Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Chen M, Nowak DG, Trotman LC.

Clin Cancer Res. 2014 Jun 15;20(12):3057-63. doi: 10.1158/1078-0432.CCR-12-3680.

13.

RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.

Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC.

Cancer Discov. 2014 Mar;4(3):318-33. doi: 10.1158/2159-8290.CD-13-0346. Epub 2014 Jan 20.

14.

Turning off AKT: PHLPP as a drug target.

Newton AC, Trotman LC.

Annu Rev Pharmacol Toxicol. 2014;54:537-58. doi: 10.1146/annurev-pharmtox-011112-140338. Review.

15.

Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors.

Labbé DP, Nowak DG, Deblois G, Lessard L, Giguère V, Trotman LC, Tremblay ML.

Mol Cancer Res. 2014 Feb;12(2):184-9. doi: 10.1158/1541-7786.MCR-13-0477. Epub 2013 Dec 30.

16.

PTEN plasticity: how the taming of a lethal gene can go too far.

Naguib A, Trotman LC.

Trends Cell Biol. 2013 Aug;23(8):374-9. doi: 10.1016/j.tcb.2013.03.003. Epub 2013 Apr 9. Review.

17.

PTEN regulation of local and long-range connections in mouse auditory cortex.

Xiong Q, Oviedo HV, Trotman LC, Zador AM.

J Neurosci. 2012 Feb 1;32(5):1643-52. doi: 10.1523/JNEUROSCI.4480-11.2012.

18.

PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML.

Cancer Res. 2012 Mar 15;72(6):1529-37. doi: 10.1158/0008-5472.CAN-11-2602. Epub 2012 Jan 26.

19.

Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.

Howitt J, Lackovic J, Low LH, Naguib A, Macintyre A, Goh CP, Callaway JK, Hammond V, Thomas T, Dixon M, Putz U, Silke J, Bartlett P, Yang B, Kumar S, Trotman LC, Tan SS.

J Cell Biol. 2012 Jan 9;196(1):29-36. doi: 10.1083/jcb.201105009. Epub 2012 Jan 2.

20.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC.

Cancer Cell. 2011 Aug 16;20(2):173-86. doi: 10.1016/j.ccr.2011.07.013.

21.

Calling on the cancer sleuths: how cell biologists will do the detective legwork of the postcancer genome era.

Trotman LC.

Mol Biol Cell. 2011 Mar 15;22(6):715. doi: 10.1091/mbc.E10-12-0956. No abstract available.

22.

Towards patient-based cancer therapeutics.

Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, Lowe SW, Guo X, Krasnitz A, Sawey ET, Sordella R, Stein L, Trotman LC, Califano A, Dalla-Favera R, Ferrando A, Iavarone A, Pasqualucci L, Silva J, Stockwell BR, Hahn WC, Chin L, DePinho RA, Boehm JS, Gopal S, Huang A, Root DE, Weir BA, Gerhard DS, Zenklusen JC, Roth MG, White MA, Minna JD, MacMillan JB, Posner BA.

Nat Biotechnol. 2010 Sep;28(9):904-6. doi: 10.1038/nbt0910-904. No abstract available.

23.

Subtle variations in Pten dose determine cancer susceptibility.

Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP.

Nat Genet. 2010 May;42(5):454-8. doi: 10.1038/ng.556. Epub 2010 Apr 18.

24.

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP.

J Clin Invest. 2010 Mar;120(3):681-93. doi: 10.1172/JCI40535. Epub 2010 Feb 8.

25.

The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells.

Janas ML, Hodson D, Stamataki Z, Hill S, Welch K, Gambardella L, Trotman LC, Pandolfi PP, Vigorito E, Turner M.

J Immunol. 2008 Jan 15;180(2):739-46.

26.

Ubiquitination regulates PTEN nuclear import and tumor suppression.

Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP.

Cell. 2007 Jan 12;128(1):141-56.

27.

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.

Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X.

Cell. 2007 Jan 12;128(1):129-39.

28.

Identification of a tumour suppressor network opposing nuclear Akt function.

Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP.

Nature. 2006 May 25;441(7092):523-7. Epub 2006 May 7.

29.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP.

Nature. 2005 Aug 4;436(7051):725-30.

30.

Nuclear targeting of adenovirus type 2 requires CRM1-mediated nuclear export.

Strunze S, Trotman LC, Boucke K, Greber UF.

Mol Biol Cell. 2005 Jun;16(6):2999-3009. Epub 2005 Apr 6.

31.

SUMO modification of Huntingtin and Huntington's disease pathology.

Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL.

Science. 2004 Apr 2;304(5667):100-4.

32.

Pten dose dictates cancer progression in the prostate.

Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP.

PLoS Biol. 2003 Dec;1(3):E59. Epub 2003 Oct 27.

33.

Non-classical export of an adenovirus structural protein.

Trotman LC, Achermann DP, Keller S, Straub M, Greber UF.

Traffic. 2003 Jun;4(6):390-402.

34.

PTEN and p53: who will get the upper hand?

Trotman LC, Pandolfi PP.

Cancer Cell. 2003 Feb;3(2):97-9. No abstract available.

35.

Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1.

Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF.

Nat Cell Biol. 2001 Dec;3(12):1092-100.

PMID:
11781571

Supplemental Content

Loading ...
Support Center